Clinical trials: Sirolimus
Breast Neoplasms, Neoplasm Metastasis
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426530
- Testing
- everolimus (RAD001)
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer
- Trial name
- NCT07634601
- Testing
- Biospecimen Collection, Computed Tomography, Elacestrant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Coronary Artery Disease
Vessel Injury in Relation With Strut Thickness Assessed by OCT
The objective of the present study is to determine the relation between vascular injury induced by the stent and strut thickness.
- Trial name
- VISTA (NCT03026465)
- Testing
- Polymer-free stent, Biodegradable-polymer stent
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy
Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fed conditions.
- Trial name
- NCT02296762
- Testing
- Sirolimus
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Advanced Renal Cell Carcinoma
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.
- Trial name
- NCT00494091
- Testing
- Temsirolimus (CCI-779)
- Where
- 24 sites in China, Japan and 1 more
- Volunteers
- 82 people
- Sponsor
- Pfizer
Lymphangioleiomyomatosis
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
RESULT is a phase II dose-escalating, open-label, safety and efficacy study to determine if there is a potential benefit of resveratrol in combination with sirolimus in patients with lymphangioleiomyomatosis (LAM).
- Trial name
- RESULT (NCT03253913)
- Testing
- Sirolimus, Resveratrol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Cincinnati
Gout Chronic, Hyperuricemia
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple…
- Trial name
- NCT02959918
- Testing
- SEL-212, SEL-037, SVP-rapamycin (SEL-110)
- Where
- 13 sites in United States
- Volunteers
- 152 people
- Sponsor
- Selecta Biosciences, Inc.
Prostate Cancer
Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
Patients with localised prostate cancer can be treated by radical prostatectomy (prostate gland removal surgery) or radiotherapy.
- Trial name
- CaNCaP02 (NCT02064608)
- Testing
- AZD2014
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Kidney Transplant
Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
During the past 15 years, however, the superior immunosuppressive efficacy of CsA and the well-known toxicity of long-term steroid therapy have prompted trials of steroid withdrawal from renal allograft recipients at various…
- Trial name
- NCT00309270
- Testing
- Campath-1H
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Organ Transplantation
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney.
- Trial name
- NCT00565773
- Testing
- Belatacept, Sirolimus, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allan D Kirk, MD, PhD
Triple-Negative Breast Cancer, Squamous Cell Lung Cancer
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Open-label, multicentre phase Ib/IIa study of AZD2014 administered with selumetinib. There are two parts to this study: a dose-escalation part in treatment-refractory advanced solid tumours and a subsequent separate expansion…
- Conditions
- Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations, Non-squamous Cell Lung Cancer With Wild-type KRAS
- Trial name
- TORCMEK (NCT02583542)
- Testing
- AZD2014, AZD6244
- Where
- 4 sites in United Kingdom
- Volunteers
- 118 people
- Sponsor
- Queen Mary University of London
Sickle Cell Disease
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can…
- Trial name
- SUN (NCT03587272)
- Testing
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Where
- 7 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Robert Nickel
Kidney Transplantation
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
- Trial name
- NCT00098241
- Testing
- Certican
- Where
- 2 sites in United States, Belgium
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Neoplasms
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD).
- Trial name
- NCT04959175
- Testing
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Coronary Atherosclerosis Due to Severely Calcified Coronary Lesion
The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC)
The primary objective of this study is to evaluate the success of lesion preparation with either rotational atherectomy or cutting/scoring balloons as well as the long term effects of a hybrid sirolimus-eluting stent in an…
- Trial name
- PREPARE-CALC (NCT02502851)
- Testing
- Rotational Atherectomy, Cutting/Scoring Balloon
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Segeberger Kliniken GmbH
Renal Cell Carcinoma
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
- Trial name
- NCT00830895
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Seoul National University Hospital
End Stage Renal Disease, Venous Stenosis
Sirolimus Use in Angioplasty for Vascular Access Extension
Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty…
- Trial name
- SAVE (NCT01595841)
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's